Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxi
ATOS: Atossa Genetics Inc.
2019-12-19 08:30:10
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
2019-12-19 08:30:10
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women